Breakdown | |||||
TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
-11.71B | 0.00 | 2.70B | 0.00 | 0.00 | 689.63K | Gross Profit |
-13.59B | -204.62K | -28.24B | -28.36B | -55.06K | 689.63K | EBIT |
-14.29M | -22.92M | -30.95M | -28.36M | -14.64M | -22.28M | EBITDA |
-13.90M | -22.25M | -30.83M | -27.70M | -13.74M | -22.20M | Net Income Common Stockholders |
-13.78M | -22.46M | -24.78M | -23.11M | -15.68M | -25.91M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
299.04K | 3.37M | 19.64M | 38.89M | 2.69M | 299.04K | Total Assets |
0.00 | 4.55M | 21.47M | 40.24M | 4.56M | 1.31M | Total Debt |
0.00 | 0.00 | 0.00 | 0.00 | 43.82M | 26.79M | Net Debt |
299.04K | -3.37M | -19.64M | -38.89M | 41.13M | 26.49M | Total Liabilities |
0.00 | 22.61M | 21.87M | 16.47M | 58.43M | 37.64M | Stockholders Equity |
-36.33M | -18.06M | -401.30K | 23.78M | -53.87M | -36.33M |
Cash Flow | Free Cash Flow | ||||
-10.79M | -15.84M | -19.12M | -13.08M | -8.43M | -15.37M | Operating Cash Flow |
-10.86M | -15.76M | -18.87M | -12.83M | -8.34M | -14.94M | Investing Cash Flow |
-73.49M | -73.56K | -250.05K | -248.98K | -95.21K | -426.47K | Financing Cash Flow |
10.82M | -407.17K | -155.60K | 49.26M | 11.11M | 11.44M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
49 Neutral | $6.90B | 0.02 | -54.05% | 2.46% | 24.91% | -3.14% | |
44 Neutral | $114.38M | ― | -53.54% | ― | 145.37% | 57.01% | |
42 Neutral | $38.57M | ― | -270.20% | ― | 144.50% | -141.91% | |
42 Neutral | $110.00M | ― | -54.21% | ― | -78.55% | -0.92% | |
42 Neutral | $531.13M | ― | -17.48% | ― | ― | ― | |
40 Underperform | $30.95M | ― | 78.50% | ― | ― | 46.74% |
MiNK Therapeutics Inc. has appointed Dr. Robert Kadlec as a Class II director on its Board, with a term lasting until 2026. Dr. Kadlec’s role includes serving on the Corporate Governance and Nominating Committee, and he has been granted options to purchase shares of MiNK’s stock, vesting over three years. His compensation package includes both cash and equity, aligning with MiNK’s non-employee director program, and his appointment was formally announced via a press release.